Our initial focus is on prostate cancer, and our current clinical programs are based on the goal to treat all stages of this disease, ranging from early stages where the cancer is still organ-confined, to late stage disease when the cancer has become metastatic and resistant to hormone therapy.
Prostate cancer is now the most commonly diagnosed type of cancer among men in the United States.
In 2000, it is estimated that approximately 180,000 men will be diagnosed as having prostate cancer in the United States, most with clinically localized disease. Caught in its earliest stages, prostate cancer has a high cure rate. New therapies, with less side-effects, are needed to make this choice easier. The situation is much worse, however, for men with more advanced disease, for whom satisfactory treatments are currently lacking. For these men, treatment options are generally not curative.